Drug Development

Research into Cold Cancers Heating Up

Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Development of Gamma-Delta T-Cell Therapies

Activation and expansion are essential for success in both autologous and allogeneic therapies.

QbD for Small-Molecule Continuous Process Development

Continuous manufacturing and a quality-by-design development approach are a natural fit.

Lilly and Entos Pharmaceuticals Partner in Research Collaboration to Develop Therapies for Multiple Neurologic Indications

February 02, 2022

Eli Lilly and Company has entered into a research and collaboration agreement with Entos Pharmaceuticals to develop new therapeutics for treating neurologic disorders.

Multispecific Analyses of Biologics Pose Multiple Challenges

February 02, 2022

The multispecific analysis of biologics is a complex task that requires appropriate strategies.

Analytical Skills Are Needed in Biologics Testing

February 02, 2022

Personnel need to be trained in various analytical skill sets for biologic drug substance testing.

Predicting Toxicity in Drug Development

February 02, 2022

Toxicology studies are an important and required aspect of drug development that are performed to ensure that drugs are deemed safe prior to patient administration and use in clinical trials.

Method Development in Demand

February 01, 2022

Experience is an invaluable asset for outsourcing partners, particularly as more challenging method development services are in demand.

Gaining Formulation Expertise through Partnerships

February 01, 2022

A key benefit for companies when outsourcing formulation development is the broad experience they can gain from a dedicated service provider, particularly for niche markets.

Evolving Demands of Process Development Services

February 01, 2022

Shifting demands from industry innovators is leading to an increased need for flexible and agile outsourcing partners offering broad and integrated models.

Fostering Orphan Drugs

February 01, 2022

CDMOs offer expertise and customization options for sponsors of orphan drugs.

PhoreMost Collaborates with Polaris and NeoCura on Cancer Therapeutics

January 28, 2022

PhoreMost has entered into separate collaboration agreements with Polaris Quantum Biotech and NeoCura Bio-Medical Technology to discover and develop novel cancer therapeutics.

BenchSci Raises $63 Million in Series C Financing Round

January 28, 2022

BenchSci, a specialist in machine learning applications for novel medicine development, has completed a Series C financing round.